Drug Profile
Nemifitide
Alternative Names: INN 00835; NetamiftideLatest Information Update: 02 Jun 2015
Price :
$50
*
At a glance
- Originator Innapharma
- Developer Tetragenex Pharmaceuticals
- Class Antidepressants; Oligopeptides
- Mechanism of Action Serotonin 2A receptor antagonists; Serotonin plasma membrane transport protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 29 Jul 2009 Nemifitide is available for licensing (http://www.tetragenex.com)
- 08 Nov 2004 A study has been added to the adverse events and Affective disorders therapeutic trials sections
- 07 Jul 2004 Data presented at the XXIVth Congress Collegium Internationale Neuro-Psychopharmacologicum (CINP-2004) have been added to the pharmacokinetics section